Curcumin and metformin-mediated chemoprevention of oral cancer is associated with inhibition of cancer stem cells

Molecular Carcinogenesis

Volumn 56, Issue 11, 2017, Pages 2446-2460

  Siddappa, Gangotri ^a   Kulsum, Safeena ^a,b   Ravindra, Doddathimmasandra Ramanjanappa ^a   Kumar, Vinay V ^c   Raju, Nalini ^a   Raghavan, Nisheena ^a   Sudheendra, Holalugunda Vittalamurthy ^a   Sharma, Anupam ^d   Sunny, Sumsum P ^a   Jacob, Tina ^e   Kuruvilla, Binu T ^f   Benny, Merina ^f   Antony, Benny ^f   Seshadri, Mukund ^g   Lakshminarayan, Padma ^c   Hicks, Wesley ^g   Suresh, Amritha ^a,g   Kuriakose, Moni A ^a,g  

^a Bommasandra Industrial Area   (India)

^b VIT UNIVERSITY   (India)

^c DrBR Ambedkar Medical College   (India)

^d Narayana Health City   (India)

^e Bangalore Institute of Dental Sciences   (India)

^f Arjuna Natural Extracts Ltd   (India)

^g ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

4NQO model; cancer stem cells; chemoprevention; curcumin; metformin; oral cancer

Indexed keywords

4 NITROQUINOLINE 1 OXIDE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; BCM 95; CD133 ANTIGEN; CURCUMIN; HERMES ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METFORMIN; NOTCH1 RECEPTOR; PROTEIN JAGGED 1; STAT3 PROTEIN; TUMOR MARKER; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER PREVENTION; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CELL MIGRATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; FEMALE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MONOTHERAPY; MOUSE; MOUTH CANCER; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; STEM CELL SELF-RENEWAL; TUMOR VOLUME; UPREGULATION; ANIMAL; C57BL MOUSE; CARCINOMA, SQUAMOUS CELL; CELL MOTION; CELL PROLIFERATION; CHEMICALLY INDUCED; DRUG EFFECTS; MOUTH; MOUTH NEOPLASMS; PATHOLOGY;

4-NITROQUINOLINE-1-OXIDE; AC133 ANTIGEN; ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; CELL PROLIFERATION; CHEMOPREVENTION; CURCUMIN; FEMALE; HYPOGLYCEMIC AGENTS; METFORMIN; MICE, INBRED C57BL; MOUTH; MOUTH NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 85023157900     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22692     Document Type: Article

References (55)

1. Felthaus O, Ettl T, Gosau M, et al. Cancer stem cell-like cells from a single cell of oral squamous carcinoma cell lines. Biochem Biophys Res Commun. 2011; 407:28–33.
2. Zhang Q, Bhola NE, Lui VW, et al. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther. 2007; 6:1414–1424.
3. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003; 23:363–398.
4. Lodi G, Sardella A, Bez C, et al. Systematic review of randomized trials for the treatment of oral leukoplakia. J Dent Educ. 2002; 66:896–902.
5. Nagao T, Warnakulasuriya S, Nakamura T, et al. Treatment of oral leukoplakia with a low-dose of beta-carotene and vitamin C supplements: a randomized controlled trial. Int J Cancer. 2015; 136:1708–1717.
6. Papadimitrakopoulou VA, Lee JJ, William WN, et al. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol. 2009; 27:599–604.
7. Kuriakose MA, Ramdas K, Dey B, et al. A randomized double-blind placebo-controlled phase IIB trial of curcumin in oral leukoplakia. Cancer Prevent Res. 2016; 9:683–691.
8. Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med. 1986; 315:1501–1505.
9. Sankaranarayanan R, Mathew B, Varghese C, et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncol. 1997; 33:231–236.
10. Kulsum S, Sudheendra HV, Pandian R, et al. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition. Mol Carcinog. 2016; 56:694–711.
11. Simple M, Suresh A, Das D, Kuriakose MA. Cancer stem cells and field cancerization of oral squamous cell carcinoma. Oral Oncol. 2015; 51:643–651.
12. Sindhu G, Balaji R, Jeyaram I, et al. Acquisition of cancer stem cell behaviour plays a role in drug resistance to combination chemotherapy and prognosis in head and neck cancer. J Stem Cell Res Ther. 2015; 5:261.
13. Abdulmajeed AA, Dalley AJ, Farah CS. Putative cancer stem cell marker expression in oral epithelial dysplasia and squamous cell carcinoma. J Oral Pathol Med. 2013; 42:755–760.
14. Carroll RE, Benya RV, Turgeon DK, et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prevent Res. 2011; 4:354–364.
15. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004; 10:6847–6854.
16. Wilken R, Veena MS, Wang MB, et al. Curcumin: a review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer. 2011; 10:12.
17. Chakravarti N, Kadara H, Yoon DJ, et al. Differential inhibition of protein translation machinery by curcumin in normal, immortalized, and malignant oral epithelial cells. Cancer Prevent Res. 2010; 3:331–338.
18. Sharma C, Kaur J, Shishodia S, et al. Curcumin downregulates smokeless tobacco-induced NF-kappaB activation and COX-2 expression in human oral premalignant and cancer cells. Toxicology. 2006; 228:1–15.
19. Hawley SA, Ross FA, Chevtzoff C, et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 2010; 11:554–565.
20. Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol. 2012; 29:1314–1327.
21. Rattan R, Ali Fehmi R, Munkarah A. Metformin: an emerging new therapeutic option for targeting cancer stem cells and metastasis. J Oncol. 2012; 2012:928127.
22. Dowling RJ, Zakikhani M, Fantus IG, et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007; 67:10804–10812.
23. Gwinn DM, Shackelford DB, Egan DF, et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008; 30:214–226.
24. Luo Q, Hu D, Hu S, et al. In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma. BMC Cancer. 2012; 12:517.
25. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004; 6:91–99.
26. Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006; 66:10269–10273.
27. Rego DF, Pavan LM, Elias ST, et al. Effects of metformin on head and neck cancer: a systematic review. Oral Oncol. 2015; 51:416–422.
28. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001; 21:2895–2900.
29. Menzies DG, Campbell IW, McBain A, Brown IR. Metformin efficacy and tolerance in obese non-insulin dependent diabetics: a comparison of two dosage schedules. Curr Med Res Opin. 1989; 11:273–278.
30. Dan HC, Cooper MJ, Cogswell PC, et al. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev. 2008; 22:1490–1500.
31. Garner JM, Fan M, Yang CH, et al. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor kappaB signaling in glioblastoma cancer stem cells regulates the Notch pathway. J Biol Chem. 2013; 288:26167–26176.
32. Sunayama J, Sato A, Matsuda K, et al. Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro Oncol. 2010; 12:1205–1219.
33. Vitale-Cross L, Molinolo AA, Martin D, et al. Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions. Cancer Prevent Res. 2012; 5:562–573.
34. Xie F, Xiao P, Chen D, Xu L, Zhang B. MiRDeepFinder: a miRNA analysis tool for deep sequencing of plant small RNAs. Plant Mol Biol. 2012; 80:75–84.
35. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29:e45.
36. Abuelba H, Cotrutz CE, Stoica BA, Stoica L, Olinici D, Petreus T. In vitro evaluation of curcumin effects on breast adenocarcinoma 2D and 3D cell cultures. Rom J Morphol Embryol. 2015; 56:71–76.
37. Choi Y, Kim SY, Park K, et al. Chemopreventive efficacy of all-trans-retinoic acid in biodegradable microspheres against epithelial cancers: results in a 4-nitroquinoline 1-oxide-induced oral carcinogenesis model. Int J Pharm. 2006; 320:45–52.
38. Kanojia D, Vaidya MM. 4-nitroquinoline-1-oxide induced experimental oral carcinogenesis. Oral Oncol. 2006; 42:655–667.
39. Kim MM, Glazer CA, Mambo E, et al. Head and neck cancer cell lines exhibit differential mitochondrial repair deficiency in response to 4NQO. Oral Oncol. 2006; 42:201–207.
40. Osei-Sarfo K, Tang XH, Urvalek AM, Scognamiglio T, Gudas LJ. The molecular features of tongue epithelium treated with the carcinogen 4-nitroquinoline-1-oxide and alcohol as a model for HNSCC. Carcinogenesis. 2013; 34:2673–2681.
41. Yu MA, Kiang A, Wang-Rodriguez J, et al. Nicotine promotes acquisition of stem cell and epithelial-to-mesenchymal properties in head and neck squamous cell carcinoma. PLoS ONE. 2012; 7:e51967.
42. An Y, Kiang A, Lopez JP, et al. Cigarette smoke promotes drug resistance and expansion of cancer stem cell-like side population. PLoS ONE. 2012; 7:e47919.
43. Goncalves Vde P, Ortega AA, Guimaraes MR, et al. Chemopreventive activity of systemically administered curcumin on oral cancer in the 4-nitroquinoline 1-oxide model. J Cell Biochem. 2015; 16:787–796.
44. Clark CA, McEachern MD, Shah SH, et al. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma. Cancer Prevent Res. 2010; 3:1586–1595.
45. Aggarwal S, Takada Y, Singh S, et al. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling. Int J Cancer. 2004; 111:679–692.
46. Memmott RM, Mercado JR, Maier CR, et al. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prevent Res. 2010; 3:1066–1076.
47. Mohammed A, Janakiram NB, Brewer M, et al. Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. Transl Oncol. 2013; 6:649–659.
48. Zhang H, Yu T, Wen L, et al. Curcumin enhances the effectiveness of cisplatin by suppressing CD133 cancer stem cells in laryngeal carcinoma treatment. Exp Ther Med. 2013; 6:1317–1321.
49. Yue W, Yang CS, DiPaola RS, et al. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. Cancer Prevent Res. 2014; 7:388–397.
50. Mao L. NOTCH mutations: multiple faces in human malignancies. Cancer Prevent Res. 2015; 8:259–261.
51. Sun W, Gaykalova DA, Ochs MF, et al. Activation of the NOTCH pathway in head and neck cancer. Cancer Res. 2014; 74:1091–1104.
52. Sakamoto K, Fujii T, Kawachi H, et al. Reduction of NOTCH1 expression pertains to maturation abnormalities of keratinocytes in squamous neoplasms. Lab Invest. 2012; 92:688–702.
53. Gokulan R, Halagowder D. Expression pattern of notch intracellular domain (NICD) and Hes-1 in preneoplastic and neoplastic human oral squamous epithelium: their correlation with c-Myc, clinicopathological factors and prognosis in oral cancer. Med Oncol. 2014; 31:126.
54. Yoshida R, Nagata M, Nakayama H, et al. The pathological significance of Notch1 in oral squamous cell carcinoma. Lab Invest. 2013; 93:1068–1081.
55. Reddy BS, Kawamori T, Lubet RA, et al. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process. Cancer Res. 1999; 59:3387–3391.